Basilea Pharmaceutica AG (BSLN.SW)

39,05 -0,70 (-1,76%) Al cierre: 05:30PM CEST

Basilea Pharmaceutica AG

Hegenheimermattweg 167b
Allschwil 4123
Switzerland
41 61 606 11 11
https://www.basilea.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 147

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. David Veitch	Chief Executive Officer	1,13M	N/A	1965
Mr. Adesh Kaul	Chief Financial Officer	N/A	N/A	1974
Dr. Gerrit Hauck Ph.D.	Chief Technology Officer	N/A	N/A	1964
Dr. Laurenz Kellenberger Ph.D.	Chief Scientific Officer	N/A	N/A	1967
Dr. Marc Engelhardt M.D.	Chief Medical Officer	N/A	N/A	1964
Dr. Peer Nils Schroder	Head of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Damian Heller	General Counsel & Corporate Secretary	N/A	N/A	1966
Mr. Andreas Kumin	Head of Corporate Development	N/A	N/A	N/A
Ms. Ursula Eberhardt	Head of Global Human Resources	N/A	N/A	1962
Mr. Mark Jones	Head of Project Management & Preclinical Development	N/A	N/A	1968

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en CHF.

Descripción

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Gobierno corporativo

El ISS Governance QualityScore de Basilea Pharmaceutica AG, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.